Qurient (South Korea)

Recent papers from Qurient (South Korea)

1. Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibitionScience Advances · 2026
2. Sublingual NS1-truncated canine influenza live attenuated vaccine induces lung-sparing immunity and supports orodispersible film deliverynpj Vaccines · 2026
3. Abstract 2975: Q702 enhances trastuzumab efficacy for HER2 + gastric cancer cells.Cancer Research · 2026
4. An Open-label Multicenter Phase 2 Trial of Telacebec for Adults with Buruli ulcer: the TREAT-BU TrialOpen Forum Infectious Diseases · 2026
5. The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimensNature Communications · 2025
6. Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and BeyondAmerican Journal of Respiratory and Critical Care Medicine · 2025
7. Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisationEuropean Respiratory Journal · 2025
8. OmniStitch: Depth-Aware Stitching Framework for Omnidirectional Vision with Multiple Cameras2024
9. A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).Journal of Clinical Oncology · 2024
10. Abstract 5712: Functional dissection of CDK7 in transcription using a highly selective CDK7 inhibitor Q901Cancer Research · 2024
11. An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus ReactivityPharmaceutics · 2024
12. Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203)Biomedicine & Pharmacotherapy · 2023
13. Influence of bridge structure manipulation on the electrochemical performance of π-conjugated molecule-bridged silicon quantum dot nanocomposite anode materials for lithium-ion batteriesNanoscale Advances · 2023
14. Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B TrialAntimicrobial Agents and Chemotherapy · 2022
15. Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy SubjectsAntimicrobial Agents and Chemotherapy · 2021
16. Synthesis and Electrochemical Performance of π-Conjugated Molecule Bridged Silicon Quantum Dot Cluster as Anode Material for Lithium-Ion BatteriesACS Omega · 2020
17. Telacebec (Q203), a New Antituberculosis AgentNew England Journal of Medicine · 2020
18. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse ModelAntimicrobial Agents and Chemotherapy · 2020
19. Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis AgentJournal of Medicinal Chemistry · 2014
20. Growth of Germanium Islands, Wires, or Films from CVD with a New PrecursorChemical Vapor Deposition · 2009